caa a22 4500 465761577 CHVBK 20180323111900.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF03000486 doi (NATIONALLICENCE)springer-10.1007/BF03000486 Phase II study of 4′-Epi-Doxorubicin in patients with untreated, extensive small Cell Lung Cancer [Elektronische Daten] [S. Eckhardt, K. Kolaric, D. Vukas, É. KÁnitz, Zs. Schoket, J. Jassem, L. Vuletic, S. Jelic, Z. Mechl, I. Koza, M. Pawlicki, B. Zuchowska] The purpose of the study was to investigate the antitumour activity and toxicity of high dose (120 mg m-2) single agent epirubicin therapy in untreated extensive small cell lung cancer patients. Out of 80 patients entered, 71 were évaluable for both antitumour activity and toxicity, 4 only for toxicity and 5 were lost for follow-up. The drug possessed a high antitumour activity, the overall response rate was 47.9% (34/71) with 4 complete remissions (CR) and 30 partial remissions (PR). The median remission duration was 3.5 months. Particular drug activity was observed in the primary tumours, lymph nodes and pleural métastases. Toxicity (leukopenia, anaemia, vomiting, reversible rhythmic cardiac disorder, stomatitis) was mild, alopecia was registered less than in adriamycin medication. One fatal congestive heart failure occurred. The actual mean survival time calculated on the basis of the data gained from 64 patients was 7.0 months (range 2-22). The high antitumour activity and no increase in toxicity justify the incorporation of high dose epirubicin into combination therapy. Humana Press Inc., 1990 High dose epirubicin nationallicence Monotherapy nationallicence Extensive small cell lung cancer nationallicence Eckhardt S. National Institute of Oncology, Budapest, Hungary aut Kolaric K. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut Vukas D. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut KÁnitz É. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut Schoket Zs National Institute of Oncology, Budapest, Hungary aut Jassem J. Medical Academy, Radiotherapy Department, Gdansk, Poland aut Vuletic L. Institute of Oncology and Radiology, Beograd, Yugoslavia aut Jelic S. Institute of Oncology and Radiology, Beograd, Yugoslavia aut Mechl Z. Research Institute for Clinical and Experimental Oncology, Brno, Czechoslovakia aut Koza I. Institute of Clinical Oncology, Bratislava, Czechoslovakia aut Pawlicki M. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut Zuchowska B. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut Medical Oncology and Tumor Pharmacotherapy Humana Press 7/1(1990-03-01), 19-23 0736-0118 7:1<19 1990 7 12032 https://doi.org/10.1007/BF03000486 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF03000486 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Eckhardt S. National Institute of Oncology, Budapest, Hungary aut NATIONALLICENCE 700 1- Kolaric K. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut NATIONALLICENCE 700 1- Vukas D. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut NATIONALLICENCE 700 1- KÁnitz É. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut NATIONALLICENCE 700 1- Schoket Zs National Institute of Oncology, Budapest, Hungary aut NATIONALLICENCE 700 1- Jassem J. Medical Academy, Radiotherapy Department, Gdansk, Poland aut NATIONALLICENCE 700 1- Vuletic L. Institute of Oncology and Radiology, Beograd, Yugoslavia aut NATIONALLICENCE 700 1- Jelic S. Institute of Oncology and Radiology, Beograd, Yugoslavia aut NATIONALLICENCE 700 1- Mechl Z. Research Institute for Clinical and Experimental Oncology, Brno, Czechoslovakia aut NATIONALLICENCE 700 1- Koza I. Institute of Clinical Oncology, Bratislava, Czechoslovakia aut NATIONALLICENCE 700 1- Pawlicki M. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut NATIONALLICENCE 700 1- Zuchowska B. Central Institute for Tumours and Allied Diseases, Zagreb, Yugoslavia aut NATIONALLICENCE 773 0- Medical Oncology and Tumor Pharmacotherapy Humana Press 7/1(1990-03-01), 19-23 0736-0118 7:1<19 1990 7 12032 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer